Fang J M, Bi A H
J Tongji Med Univ. 1989;9(2):91-4. doi: 10.1007/BF02908933.
The activity of IL-2 produced by mononuclear cells in draining lymph-onde and peripheral blood from patients with cancer was investigated. It was found that, though the activity of IL-2 produced by peripheral blood mononuclear cells from these patients became much lower, the activity of IL-2 produced by draining lymph node mononuclear cells from the same donors showed no decline, in contrast to non-malignant patients and healthy controls. What is more, the NK cells of tumor draining lymph-nodes responded as strong to xenogenous IL-2 as those of draining lymphnodes from patients with non-malignant disease. The results suggested that some of the immune functions of tumor draining lymph-node mononuclear cells might be more stable than those of peripheral blood mononuclear cells in patients suffering from cancer, and that local injection of xenogenous IL-2 might enhance the anti-cancer activity of tumor draining lymph-node.
对癌症患者引流淋巴结和外周血中单核细胞产生的白细胞介素-2(IL-2)活性进行了研究。结果发现,尽管这些患者外周血单核细胞产生的IL-2活性大幅降低,但与非恶性疾病患者和健康对照相比,同一供体引流淋巴结单核细胞产生的IL-2活性并未下降。此外,肿瘤引流淋巴结的自然杀伤细胞(NK细胞)对外源性IL-2的反应与非恶性疾病患者引流淋巴结的NK细胞一样强烈。结果表明,癌症患者肿瘤引流淋巴结单核细胞的某些免疫功能可能比外周血单核细胞的免疫功能更稳定,并且局部注射外源性IL-2可能增强肿瘤引流淋巴结的抗癌活性。